|Awarded On||February 16, 2022|
|Title||Simultaneous targeting of LGR4/5/6 for the treatment of gastrointestinal cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Qingyun Liu|
|Cancer Sites||Colorectal, Gallbladder, Liver and Intrahepatic Bile Duct, Stomach|
Cancers of the gastrointestinal tract, including colorectal, liver, and stomach cancer, represent major types of cancer with high morbidity and mortality in Texas and the rest of the world. In particular, liver cancer is becoming increasingly more common in this state with few treatment options available.
This project is aimed at creating a novel class of therapeutics that targets a group of receptors with increased levels in cancers of the digestive system. LGR4, 5, and 6 (leucine-rich repeat containing, G protein-coupled receptor 4, 5, 6) are three related proteins with critical roles in tumor formation and metastasis. Aberrant activation of the three receptors has been shown to drive...